Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Angela Rita Sementa is active.

Publication


Featured researches published by Angela Rita Sementa.


European Journal of Cancer | 2009

Neuroblastoma in the newborn. A study of the Italian Neuroblastoma Registry

Anna Rita Gigliotti; Andrea Di Cataldo; Stefania Sorrentino; Stefano Parodi; Antonino Rizzo; Piero Buffa; Claudio Granata; Angela Rita Sementa; Anna Maria Fagnani; Massimo Provenzi; Arcangelo Prete; Carmelita D’Ippolito; Anna Clerico; Aurora Castellano; Gian Paolo Tonini; Massimo Conte; Alberto Garaventa; Bruno De Bernardi

AIMnPresenting features, treatment and outcome of 134 newborns with neuroblastoma diagnosed over a 27-year period are described.nnnMETHODSnAnalyses were performed on the entire cohort and on patients distributed over three periods of diagnosis.nnnRESULTSnTwenty-seven tumours (20.1%) were detected prenatally. Localised disease prevailed (65.7%) with an increase of stage 1 patients over time from 18.8% to 46.5%. Disseminated disease accounted for 34.3% of tumours with only one stage 4 and 45 stage 4S. Five-year overall survival (OS) of the entire cohort was 88.3%. Five/88 patients with localised disease died, including three who died of complications (OS, 95.3%). The only stage 4 patient survived. Eleven/45 stage 4S patients died, including 7/18 symptomatic and 4/27 asymptomatic (OS, 74.1%).nnnCONCLUSIONnThe outcome of neuroblastoma in newborns is excellent. In localised tumours, surgery-related deaths outnumbered deaths due to disease. Symptomatic stage 4S patients were at greater risk of dying.


Critical Reviews in Oncology Hematology | 2016

Neuroblastoma (Peripheral neuroblastic tumours)

Roberto Luksch; Maria Rita Castellani; Paola Collini; Bruno De Bernardi; Massimo Conte; Claudio Gambini; Lorenza Gandola; Alberto Garaventa; Davide Biasoni; Marta Podda; Angela Rita Sementa; Gemma Gatta; Gian Paolo Tonini

Peripheral neuroblastic tumours (PNTs), a family of tumours arising in the embryonal remnants of the sympathetic nervous system, account for 7-10% of all tumours in children. In two-thirds of cases, PNTs originate in the adrenal glands or the retroperitoneal ganglia. At least one third present metastases at onset, with bone and bone marrow being the most frequent metastatic sites. Disease extension, MYCN oncogene status and age are the most relevant prognostic factors, and their influence on outcome have been considered in the design of the recent treatment protocols. Consequently, the probability of cure has increased significantly in the last two decades. In children with localised operable disease, surgical resection alone is usually a sufficient treatment, with 3-year event-free survival (EFS) being greater than 85%. For locally advanced disease, primary chemotherapy followed by surgery and/or radiotherapy yields an EFS of around 75%. The greatest problem is posed by children with metastatic disease or amplified MYCN gene, who continue to do badly despite intensive treatments. Ongoing trials are exploring the efficacy of new drugs and novel immunological approaches in order to save a greater number of these patients.


Biomaterials | 2015

Neuroblastoma-targeted nanocarriers improve drug delivery and penetration, delay tumor growth and abrogate metastatic diffusion

Irene Cossu; Gianluca Bottoni; Monica Loi; Laura Emionite; Alice Bartolini; Daniela Di Paolo; Chiara Brignole; Francesca Piaggio; Patrizia Perri; Angelina Sacchi; Flavio Curnis; Maria Cristina Gagliani; Silvia Bruno; Cecilia Marini; Alessandro Gori; Renato Longhi; Daniele Murgia; Angela Rita Sementa; Michele Cilli; Carlo Tacchetti; Angelo Corti; Gianmario Sambuceti; Serena Marchiò; Mirco Ponzoni; Fabio Pastorino

Selective tumor targeting is expected to enhance drug delivery and to decrease toxicity, resulting in an improved therapeutic index. We have recently identified the HSYWLRS peptide sequence as a specific ligand for aggressive neuroblastoma, a childhood tumor mostly refractory to current therapies. Here we validated the specific binding of HSYWLRS to neuroblastoma cell suspensions obtained either from cell lines, animal models, or Schwannian-stroma poor, stage IV neuroblastoma patients. Binding of the biotinylated peptide and of HSYWLRS-functionalized fluorescent quantum dots or liposomal nanoparticles was dose-dependent and inhibited by an excess of free peptide. In animal models obtained by the orthotopic implant of either MYCN-amplified or MYCN single copy human neuroblastoma cell lines, treatment with HSYWLRS-targeted, doxorubicin-loaded Stealth Liposomes increased tumor vascular permeability and perfusion, enhancing tumor penetration of the drug. This formulation proved to exert a potent antitumor efficacy, as evaluated by bioluminescence imaging and micro-PET, leading to (i) delay of tumor growth paralleled by decreased tumor glucose consumption, and (ii) abrogation of metastatic spreading, accompanied by absence of systemic toxicity and significant increase in the animal life span. Our findings are functional to the design of targeted nanocarriers with potentiated therapeutic efficacy towards the clinical translation.


Pediatric Transplantation | 2011

HHV-8-related visceral Kaposi’s sarcoma following allogeneic HSCT: Report of a pediatric case and literature review

Ilaria Sala; Maura Faraci; Gian Michele Magnano; Angela Rita Sementa; Eddi Di Marco; Alberto Garaventa; Concetta Micalizzi; Edoardo Lanino; Giuseppe Morreale; Cristina Moroni; Elio Castagnola

Sala I, Faraci M, Magnano GM, Sementa A, di Marco E, Garaventa A, Micalizzi C, Lanino E, Morreale G, Moroni C, Castagnola E. HHV‐8‐related visceral Kaposi’s sarcoma following allogeneic HSCT: Report of a pediatric case and literature review.u2028Pediatr Transplantation 2011: 15:E8–E11.


BMC Bioinformatics | 2016

Artificial neural network classifier predicts neuroblastoma patients' outcome

Davide Cangelosi; Simone Pelassa; Martina Morini; Massimo Conte; Maria Carla Bosco; Alessandra Eva; Angela Rita Sementa; Luigi Varesio

BackgroundMore than fifty percent of neuroblastoma (NB) patients with adverse prognosis do not benefit from treatment making the identification of new potential targets mandatory. Hypoxia is a condition of low oxygen tension, occurring in poorly vascularized tissues, which activates specific genes and contributes to the acquisition of the tumor aggressive phenotype. We defined a gene expression signature (NB-hypo), which measures the hypoxic status of the neuroblastoma tumor. We aimed at developing a classifier predicting neuroblastoma patients’ outcome based on the assessment of the adverse effects of tumor hypoxia on the progression of the disease.MethodsMulti-layer perceptron (MLP) was trained on the expression values of the 62 probe sets constituting NB-hypo signature to develop a predictive model for neuroblastoma patients’ outcome. We utilized the expression data of 100 tumors in a leave-one-out analysis to select and construct the classifier and the expression data of the remaining 82 tumors to test the classifier performance in an external dataset. We utilized the Gene set enrichment analysis (GSEA) to evaluate the enrichment of hypoxia related gene sets in patients predicted with “Poor” or “Good” outcome.ResultsWe utilized the expression of the 62 probe sets of the NB-Hypo signature in 182 neuroblastoma tumors to develop a MLP classifier predicting patients’ outcome (NB-hypo classifier). We trained and validated the classifier in a leave-one-out cross-validation analysis on 100 tumor gene expression profiles. We externally tested the resulting NB-hypo classifier on an independent 82 tumors’ set. The NB-hypo classifier predicted the patients’ outcome with the remarkable accuracy of 87xa0%. NB-hypo classifier prediction resulted in 2xa0% classification error when applied to clinically defined low-intermediate risk neuroblastoma patients. The prediction was 100xa0% accurate in assessing the death of five low/intermediated risk patients. GSEA of tumor gene expression profile demonstrated the hypoxic status of the tumor in patients with poor prognosis.ConclusionsWe developed a robust classifier predicting neuroblastoma patients’ outcome with a very low error rate and we provided independent evidence that the poor outcome patients had hypoxic tumors, supporting the potential of using hypoxia as target for neuroblastoma treatment.


Disease Models & Mechanisms | 2014

Development of hepatocellular adenomas and carcinomas in mice with liver-specific G6Pase-α deficiency

Roberta Resaz; Cristina Vanni; Daniela Segalerba; Angela Rita Sementa; Luca Mastracci; Federica Grillo; Daniele Murgia; Maria Carla Bosco; Janice Y. Chou; Ottavia Barbieri; Luigi Varesio; Alessandra Eva

Glycogen storage disease type 1a (GSD-1a) is caused by a deficiency in glucose-6-phosphatase-α (G6Pase-α), and is characterized by impaired glucose homeostasis and a high risk of developing hepatocellular adenomas (HCAs). A globally G6Pase-α-deficient (G6pc−/−) mouse model that shows pathological features similar to those of humans with GSD-1a has been developed. These mice show a very severe phenotype of disturbed glucose homeostasis and rarely live beyond weaning. We generated liver-specific G6Pase-α-deficient (LS‑G6pc−/−) mice as an alternative animal model for studying the long-term pathophysiology of the liver and the potential treatment strategies, such as cell therapy. LS‑G6pc−/− mice were viable and exhibited normal glucose profiles in the fed state, but showed significantly lower blood glucose levels than their control littermates after 6 hours of fasting. LS‑G6pc−/− mice developed hepatomegaly with glycogen accumulation and hepatic steatosis, and progressive hepatic degeneration. Ninety percent of the mice analyzed developed amyloidosis by 12 months of age. Finally, 25% of the mice sacrificed at age 10–20 months showed the presence of multiple HCAs and in one case late development of hepatocellular carcinoma (HCC). In conclusion, LS‑G6pc−/− mice manifest hepatic symptoms similar to those of human GSD-1a and, therefore, represent a valid model to evaluate long-term liver pathogenesis of GSD-1a.


Pediatric Blood & Cancer | 2017

Comparative retrospective study on the modalities of biopsying peripheral neuroblastic tumors: a report from the Italian Pediatric Surgical Oncology Group (GICOP)

Stefano Avanzini; Maria Grazia Faticato; Alessandro Crocoli; Calogero Virgone; Camilla Viglio; Elisa Severi; Anna Maria Fagnani; Giovanni Cecchetto; Giovanna Riccipetitoni; Bruno Noccioli; Ernesto Leva; Angela Rita Sementa; Girolamo Mattioli; Alessandro Inserra

Peripheral neuroblastic tumors are the most common extracranial solid neoplasms in children. Early and adequate tissue sampling may speed up the diagnostic process and ensure a prompt start of optimal treatment whenever needed. Different biopsy techniques have been described. The purpose of this multi‐center study is to evaluate the accuracy and safety of the various examined techniques and to determine whether a preferential procedure exists.


Cancer Genetics and Cytogenetics | 2010

Trisomy 17 in congenital plexiform (multinodular) cellular schwannoma

Elisa Tassano; Angela Rita Sementa; Elisa Tavella; Alberto Garaventa; Claudio Panarello; Cristina Morerio

Plexiform (multinodular) cellular schwannomas are rare tumors, not associated with neurofibromatosis type 1, that occur more often in children and can be congenital. Their biology is benign and is characterized by the tendency to recur locally without being metastatic. Cytogenetic studies in adult cases of schwannoma indicate a complete or partial loss of chromosome 22 as the most common abnormality. Only two cytogenetic studies describe cases in children, one of which concerned a congenital cellular plexiform schwannoma. Here, we report the cytogenetic analysis of a second case in an 8-month-old boy with recurrence of trisomy 17.


Blood Cells Molecules and Diseases | 2018

The unusual association between Neuroblastoma and Gaucher Disease: Case report and review of the literature

Annalisa Madeo; Alberto Garaventa; Angela Rita Sementa; Chiara Suffia; Maja Di Rocco

Gaucher disease (GD) patients have an increased risk of cancer, in particular of hematological origin, while the association between GD and Neuroblastoma (NBL) has never been described. Here we report the case of an adolescent diagnosed with NBL, also presenting splenomegaly and persistent thrombocytopenia. The association with GD, suggested by the histological findings on bone marrow biopsy, was confirmed by enzymatic and genetic tests. The possible pathogenetic mechanisms are briefly reviewed. The evidence of this new association supports the necessity of further studies on GD comorbidities and the need of systematic data collection and analysis, potentially through an international registry. A greater attention for GD in the hemato-oncological field is needed, in order to avoid underdiagnosis and to optimize treatment strategies.


British Journal of Cancer | 2018

Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study

Ana P. Berbegall; Dominik Bogen; Ulrike Pötschger; Klaus Beiske; Nick Bown; Valérie Combaret; Raffaella Defferrari; Marta Jeison; Katia Mazzocco; Luigi Varesio; Ales Vicha; Shifra Ash; Victoria Castel; Carole Coze; Ruth Ladenstein; Cormac Owens; Vassilios Papadakis; Ellen Ruud; Gabriele Amann; Angela Rita Sementa; Samuel Navarro; Peter F. Ambros; Rosa Noguera; Inge M. Ambros

BackgroundIn neuroblastoma (NB), the most powerful prognostic marker, the MYCN amplification (MNA), occasionally shows intratumoural heterogeneity (ITH), i.e. coexistence of MYCN-amplified and non-MYCN-amplified tumour cell clones, called heterogeneous MNA (hetMNA). Prognostication and therapy allocation are still unsolved issues.MethodsThe SIOPEN Biology group analysed 99 hetMNA NBs focussing on the prognostic significance of MYCN ITH.ResultsPatients <18 months (18u2009m) showed a better outcome in all stages as compared to older patients (5-year OS in localised stages: <18u2009m: 0.95u2009±u20090.04, >18u2009m: 0.67u2009±u20090.14, pu2009=u20090.011; metastatic: <18u2009m: 0.76u2009±u20090.15, >18u2009m: 0.28u2009±u20090.09, pu2009=u20090.084). The genomic background’, but not MNA clone sizes, correlated significantly with relapse frequency and OS. No relapses occurred in cases of only numerical chromosomal aberrations. Infiltrated bone marrows and relapse tumour cells mostly displayed no MNA. However, one stage 4s tumour with segmental chromosomal aberrations showed a homogeneous MNA in the relapse.ConclusionsThis study provides a rationale for the necessary distinction between heterogeneous and homogeneous MNA. HetMNA tumours have to be evaluated individually, taking age, stage and, most importantly, genomic background into account to avoid unnecessary upgrading of risk/overtreatment, especially in infants, as well as in order to identify tumours prone to developing homogeneous MNA.

Collaboration


Dive into the Angela Rita Sementa's collaboration.

Top Co-Authors

Avatar

Massimo Conte

Istituto Giannina Gaslini

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Patrizia Perri

Istituto Giannina Gaslini

View shared research outputs
Top Co-Authors

Avatar

Luigi Varesio

Laboratory of Molecular Biology

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Angelo Corti

Vita-Salute San Raffaele University

View shared research outputs
Top Co-Authors

Avatar

Anna Maria Fagnani

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

View shared research outputs
Top Co-Authors

Avatar

Chiara Brignole

Istituto Giannina Gaslini

View shared research outputs
Researchain Logo
Decentralizing Knowledge